Clin Nutr Res.  2018 Jan;7(1):40-47. 10.7762/cnr.2018.7.1.40.

Dietary Intake of Thiamine in Migraine Patients and Healthy Subjects: a Case-Control Study

• Faraji H
• Paknahad Z
• Chitsaz A

• KMID: 2402341
• DOI: http://doi.org/10.7762/cnr.2018.7.1.40

Abstract

The migraine headache is a disease related to the neurovascular system, which affects 10%-20% of people, worldwide. Recent evidences suggested a relation between thiamine status and migraine headaches. The current study was undertaken to assess dietary intake of the thiamine in migraine patients and to evaluate its association with the frequency of migraine attacks. In a case-control design, the current study was performed on 50 migraine patients and 50 healthy people, 20-60 years old in Isfahan, Iran, in 2017. Information about dietary intake was collected by Food frequency questionnaire and analyzed using the Nutritionist version 4 (N4) software (Tinuviel Software). Information about the history of disease was collected by demographic questionnaire. Analysis of covariance and independent t-test were used for data analysis and p value less than 0.05 was considered significant. Mean age, weight, height, and body mass index of participants were 35.1 ± 9.8 years, 65.3 ± 10.4 kg, 162.5 ± 8.4 cm, and 24.7 ± 4.0 kg/m², respectively. Dietary intake of thiamine among the migraine patients was lower than that in the healthy participants (p < 0.001). Migraine patients with the high frequency attacks had significantly lower intake of thiamine compared with moderate frequency attacks group (p = 0.010), however, it was not significant after adjusting for energy intake (p = 0.410, p = 0.240). Dietary intake of thiamine in migraine patients was not significantly different in comparing with healthy subjects. In addition, no significant correlation between thiamine intake and the frequency of migraine attacks was observed.

Keyword

Diet; Thiamine; Migraine disorders; Frequency

MeSH Terms

Body Mass Index
Case-Control Studies*
Diet
Energy Intake
Healthy Volunteers*
Humans
Iran
Migraine Disorders*
Nutritionists
Statistics as Topic
Thiamine*
Thiamine

Reference

1. Hougaard A, Amin FM, Christensen CE, Younis S, Wolfram F, Cramer SP, Larsson HB, Ashina M. Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain. 2017; 140:1633–1642.

2. Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain. 2016; 17:104.

3. Inaloo S, Dehghani SM, Farzadi F, Haghighat M, Imanieh MH. A comparative study of celiac disease in children with migraine headache and a normal control group. Turk J Gastroenterol. 2011; 22:32–35.

4. Monteith TS, Gardener H, Rundek T, Elkind MS, Sacco RL. Migraine and risk of stroke in older adults: Northern Manhattan Study. Neurology. 2015; 85:715–721.

5. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; 33:629–808.

6. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988; 8:Suppl 7. 1–96.

7. Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and treatment. N Engl J Med. 2002; 346:257–270.

8. Irwin S, Barmherzig R, Gelfand A. Recurrent gastrointestinal disturbance: abdominal migraine and cyclic vomiting syndrome. Curr Neurol Neurosci Rep. 2017; 17:21.

9. Mollaoğlu M. Trigger factors in migraine patients. J Health Psychol. 2013; 18:984–994.

10. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet. 2000; 96:762–764.

11. Camboim Rockett F, Castro K, Rossoni de Oliveira V, da Silveira Perla A, Fagundes Chaves ML, Schweigert Perry ID. Perceived migraine triggers: do dietary factors play a role? Nutr Hosp. 2012; 27:483–489.

12. Lea R, Colson N, Quinlan S, Macmillan J, Griffiths L. The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. Pharmacogenet Genomics. 2009; 19:422–428.

13. Menon S, Lea RA, Roy B, Hanna M, Wee S, Haupt LM, Oliver C, Griffiths LR. Genotypes of the MTHFR C677T and MTRR A66G genes act independently to reduce migraine disability in response to vitamin supplementation. Pharmacogenet Genomics. 2012; 22:741–749.

14. Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007; 6:442–455.

15. Isenberg-Grzeda E, Kutner HE, Nicolson SE. Wernicke-Korsakoff-syndrome: under-recognized and under-treated. Psychosomatics. 2012; 53:507–516.

16. Prakash S, Kumar Singh A, Rathore C. Chronic migraine responding to intravenous thiamine: a report of two cases. Headache. 2016; 56:1204–1209.

17. Gaul C, Diener HC, Danesch U. Migravent® Study Group. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain. 2015; 16:516.

18. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001; 56:S20–S28.

19. Hosseini Esfahani H, Asghari G, Mirmiran P, Azizi F. Reproducibility and relative validity of food group intake in a food frequency questionnaire developed for the Tehran Lipid and Glucose Study. J Epidemiol. 2010; 20:150–158.

20. Linde M, Steiner TJ, Chisholm D. Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries. J Headache Pain. 2015; 16:15.

21. Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, Varon SF, Blumenfeld AM, Katsarava Z, Pascual J, Lanteri-Minet M, Cortelli P, Martelletti P. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012; 13:361–378.

22. Taşkapilioğlu Ö, Karli N. Assessment of quality of life in migraine. Noro Psikiyatri Arsivi. 2013; 50:S60–S64.

23. Hickey S. The vitamin cure for migraine. Laguna Beach (CA): Basic Health Publications;2010.

24. Shaik MM, Gan SH. Vitamin supplementation as possible prophylactic treatment against migraine with aura and menstrual migraine. BioMed Res Int. 2015; 2015:469529.

25. Di Rosa G, Attinà S, Spanò M, Ingegneri G, Sgrò DL, Pustorino G, Bonsignore M, Trapani-Lombardo V, Tortorella G. Efficacy of folic acid in children with migraine, hyperhomocysteinemia and MTHFR polymorphisms. Headache. 2007; 47:1342–1344.

26. Bianchi A, Salomone S, Caraci F, Pizza V, Bernardini R, D'Amato CC. Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis. Vitam Horm. 2004; 69:297–312.

27. Yee AJ, Schoenen J. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology. 1999; 52:431–432.

28. Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhäupl KM, Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol. 2004; 11:475–477.

29. Bâ A. Metabolic and structural role of thiamine in nervous tissues. Cell Mol Neurobiol. 2008; 28:923–931.

30. Mkrtchyan G, Aleshin V, Parkhomenko Y, Kaehne T, Di Salvo ML, Parroni A, Contestabile R, Vovk A, Bettendorff L, Bunik V. Molecular mechanisms of the non-coenzyme action of thiamin in brain: biochemical, structural and pathway analysis. Sci Rep. 2015; 5:12583.

31. Menon S, Nasir B, Avgan N, Ghassabian S, Oliver C, Lea R, Smith M, Griffiths L. The effect of 1 mg folic acid supplementation on clinical outcomes in female migraine with aura patients. J Headache Pain. 2016; 17:60.